Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have used human lung cancer cell lines carrying a plasmid vector containing a (CA)(13) microsatellite sequence to study frameshift mutations mediated by ROS-generating chemicals paraquat and hydrogen peroxide.
|
10910953 |
2000 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ROS1 rearrangements define a unique molecular class of lung cancers.
|
22215748 |
2012 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for ROS1.
|
22327623 |
2012 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
|
22617245 |
2012 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ROS1 IHC assay described here is a valuable tool for identifying patients expressing mutant ROS1 and could be routinely applied in clinical practice to detect lung cancers that may be responsive to targeted therapies.
|
22661537 |
2012 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to the lung cancer-related genes (TP53, EGFR, KRAS, PIK3CA, and ROS1), this study revealed "novel" genes not previously implicated in NSCLC.
|
22696596 |
2012 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also report in lung cancer the GOPC-ROS1 fusion originally discovered and characterized in a glioma cell line.
|
23052255 |
2012 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ROS1 encodes a tyrosine kinase that is abnormally expressed and translocated in brain and lung cancers.
|
23415111 |
2013 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To better understand these tumors, we examined 799 surgically resected non-small cell lung cancers by reverse transcriptase polymerase chain reaction and identified 15 tumors harboring ROS1 fusion transcripts (2.5% of adenocarcinomas).
|
23426121 |
2013 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), has also recently shown efficacy in the treatment of lung cancers with ROS1 translocations.
|
23724914 |
2013 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the present study indicates that the new synthetic derivative MA-1 triggers mitochondrial apoptosis through ROS generation and regulation of MAPKs and may be a potent therapeutic agent against human lung cancer.
|
24161344 |
2013 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As lung cancers with ROS1 rearrangements comprise only 1-3% of lung adenocarcinomas, patients with such tumors must be identified to gain optimal benefit from molecular therapy.
|
24186139 |
2014 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All 27 lung cancer specimens that were negative for ROS1 rearrangements by genetic testing had no to low ROS1 protein expression.
|
25467930 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1.
|
25667280 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although high response rates and disease control have been observed in lung cancer patients bearing rearranged ROS1 tumors (ROS1+) treated with the kinase inhibitor crizotinib, many of these patients eventually relapse.To identify mechanisms of resistance to ROS1 inhibitors we generated resistant cells from HCC78 lung cancer cells bearing the SLC34A2-ROS1 rearrangement.
|
25691052 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EML4-ALK inversion and ROS1 fusions emerge as common fusion abnormalities in IMT, closely recapitulating the pattern seen in lung cancer.
|
25723109 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activating alterations in several potential driver oncogenic genes have been identified, including EGFR, ROS1 and ALK and understanding of their molecular mechanisms underlying development, progression, and survival of lung cancer has led to the design of personalized treatments that have produced superior clinical outcomes in tumours harbouring these mutations.
|
25773789 |
2015 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
|
25789833 |
2015 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
|
26149475 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study assessed the computed tomography (CT) imaging features of patients with RET- and ROS1-rearranged lung cancers.
|
26424208 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
|
26673800 |
2016 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The identification of the location of the rs9387478 single nucleotide polymorphism in the genomic interval containing the DCBLD1 and ROS1 genes, together with the finding that the rs9387478 polymorphism correlates with EGFR mutation status, may have important implications for therapeutic approaches targeting EGFR or ROS1 in patients with lung cancer.
|
26689248 |
2016 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oncologists are requesting testing for ROS1 translocations which predict susceptibility to crizotinib, already approved for ALK positive lung cancers.
|
26703797 |
2016 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed cases with lung adenocarcinomas for representative genomic aberrations, evaluated the response to the multitargeted MET/ALK/ROS1 crizotinib TKI in cases with MET aberrations and profiled lung cancer cell lines with the aforementioned genomic changes.
|
26791794 |
2015 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data suggest that each of these two ROS1-fusion genes acts as a driver for the pathogenesis of lung adenocarcinoma in vivo The TG mice developed in this study are expected to serve as valuable tools for exploring novel therapeutic agents against ROS1-fusion-positive lung cancer.
|
26964870 |
2016 |